昆藥集團(600422.SH)擬在海南設子公司以推動公司營銷轉型
格隆匯10月20日丨昆藥集團(600422.SH)公佈,為進一步鞏固和提升公司對單體或中小連鎖藥店供應鏈合作粘性、支持公司營銷轉型。昆藥商業擬在海南生態軟件園新設公司,名稱暫定為“海南九如醫療科技有限公司”(以下簡稱“海南公司”)。
海南公司擬向海南省衞健委審批辦提交醫療機構設置申請書(遠程中心、互聯網醫院)。如海南公司獲得海南省衞健委遠程中心、互聯網醫院的批覆,授權公司管理團隊決策投資註冊互聯網醫院,註冊資本500萬元。
海南公司註冊資本為人民幣1,000萬元整,以現金認繳出資,實際出資進度根據公司經營需求分期出資。海南公司經營範圍:互聯網科技創新平台,社區遠程健康管理服務,家庭遠程健康管理服務,應用軟件開發,互聯網批發,零售醫藥及醫療器材,健康諮詢,醫療服務,醫療、醫藥諮詢服務,創業市場開拓諮詢與策劃服務,科技信息諮詢服務等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.